Lexaria Bioscience Corp (NASDAQ: LEXX) on Tuesday, plunged -5.25% from the previous trading day, before settling in for the closing price of $1.47. Within the past 52 weeks, LEXX’s price has moved between $1.15 and $4.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 40.03% annually for the last half of the decade. The company achieved an average annual earnings per share of -24.47%. With a float of $16.27 million, this company’s outstanding shares have now reached $17.45 million.
In an organization with 7 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.25%, operating margin of -1469.98%, and the pretax margin is -1474.54%.
Lexaria Bioscience Corp (LEXX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lexaria Bioscience Corp is 7.31%, while institutional ownership is 8.13%. The most recent insider transaction that took place on Dec 03 ’24, was worth 67,175. In this transaction Chief Executive Officer of this company bought 27,172 shares at a rate of $2.47, taking the stock ownership to the 50,000 shares. Before that another transaction happened on Dec 02 ’24, when Company’s Chief Executive Officer bought 22,828 for $2.24, making the entire transaction worth $51,217. This insider now owns 22,828 shares in total.
Lexaria Bioscience Corp (LEXX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -24.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.84% during the next five years compared to 21.61% growth over the previous five years of trading.
Lexaria Bioscience Corp (NASDAQ: LEXX) Trading Performance Indicators
Lexaria Bioscience Corp (LEXX) is currently performing well based on its current performance indicators. A quick ratio of 29.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 48.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.49, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of Lexaria Bioscience Corp (LEXX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.2 million. That was better than the volume of 0.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.78%. Additionally, its Average True Range was 0.16.
During the past 100 days, Lexaria Bioscience Corp’s (LEXX) raw stochastic average was set at 13.95%, which indicates a significant decrease from 41.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.79% in the past 14 days, which was higher than the 79.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6832, while its 200-day Moving Average is $2.5718. However, in the short run, Lexaria Bioscience Corp’s stock first resistance to watch stands at $1.6573. Second resistance stands at $1.9246. The third major resistance level sits at $2.1192. If the price goes on to break the first support level at $1.1954, it is likely to go to the next support level at $1.0008. Assuming the price breaks the second support level, the third support level stands at $0.7335.
Lexaria Bioscience Corp (NASDAQ: LEXX) Key Stats
Market capitalization of the company is 24.40 million based on 17,553K outstanding shares. Right now, sales total 460 K and income totals -5,800 K. The company made 180 K in profit during its latest quarter, and -2,700 K in sales during its previous quarter.
